The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | Updated BSH guidelines for managing DLBCL
Cathy Burton, MB BChir, MD, MRCP, FRCPath, St James’s University Hospital, Leeds, UK, introduces the updated British Society for Hematology (BSH) guidelines for managing newly diagnosed large B-cell lymphoma (DLBCL). The guidelines encompass novel first-line therapies like Pola-R-CHP, second-line CAR-T therapies, and third-line bispecific antibodies. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Funded by Kite Gilead to attend meeting.
